Avidity Biosciences (RNA)
(Delayed Data from NSDQ)
$46.30 USD
+1.18 (2.62%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $46.29 -0.01 (-0.02%) 6:48 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
[RNA]
Reports for Purchase
Showing records 21 - 40 ( 62 total )
Industry: Medical - Biomedical and Genetics
We initiate with a Neutral rating and a $12 price target
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Preview: RNA to Present Further Promising Drisapersen Analyses at AAN - Recent FDA Comments Signal Greater Receptiveness in DMD - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
Preview: RNA to Present Further Promising Drisapersen Analyses at AAN - Recent FDA Comments Signal Greater Receptiveness in DMD - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
Preview: RNA to Present Further Promising Drisapersen Analyses at AAN - Recent FDA Comments Signal Greater Receptiveness in DMD - Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
Q4 Update - Demand V Results Misunderstood - Duration of Response Supports Drisapersen''s Efficacy - Reiterate
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
MDA Conference Preview: DMD and SMA Updates - RNA''s DEMAND V Data Monday
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
MDA Conference Preview: DMD and SMA Updates - RNA''s DEMAND V Data Monday
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 17
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Upgrading to OUTPERFORM and Increasing Price Target to $12; Drisapersen Data Highlights Opportunity with Long- Term Dosing and Validates Pipeline
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Phase III Post-hoc Analysis Promising - Support Potential for Optimized Pipeline Compounds - Awaiting Further Clarity on Path Forward
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
Phase III Post-hoc Analysis Promising - Support Potential for Optimized Pipeline Compounds - Awaiting Further Clarity on Path Forward
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
Regains Drisapersen Rights - Further Analysis Pending RNA''s Receipt of Data and to Inform Potentially More Potent Pipeline - Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L